Walleye Capital
ANIK icon

Walleye Capital’s Anika Therapeutics ANIK Stock Holding History

Walleye Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,665
Closed -$353K – 1329
2021
Q1 		$353K Buy
+8,665
New +$329K 0.02% 709
2020
Q1 		– Sell
-1,683
Closed -$87K – 903
2019
Q4 		$87K Sell
1,683
-4,099
-71% -$238K 0.01% 1389
2019
Q3 		$317K Buy
+5,782
New +$297K 0.02% 959

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's ANIK Position: Q2 2021 in Review

Walleye Capital sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 8,665 shares — an estimated $353K sold.

Walleye Capital first reported a position in ANIK in Q3 2019 and held it in 3 quarters. The position peaked at $353K in Q1 2021. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

  • Walleye Capital reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Walleye Capital sold 8,665 Anika Therapeutics shares in Q2 2021, an estimated $353K.
  • Walleye Capital first reported a position in Anika Therapeutics in Q3 2019 and held it in 3 quarters.
  • Walleye Capital's Anika Therapeutics position peaked at $353K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on Walleye Capital's 13F filing for Q2 2021, filed 16 Aug 2021.